Safety and Immunogenicity of Varicella Vaccination in Children and Adolescents Living With HIV: A Systematic Review.

Pediatr Infect Dis JMay 11, 2026 (epub)
Clinical ResearchInfectious DiseasesPediatrics

Mona Marin, Likhita Raparti, Jessica Leung et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the safety and immunogenicity of varicella vaccination in HIV-positive children. Analyzing 18 studies, it found that local reactions occurred in less than 21% of vaccinees after the first dose, with serious adverse events only in severely immunosuppressed individuals. Antibody responses were observed in 60%-79% after the second dose.

Key findings

  • Local reactions occurred in <21% of vaccinees after dose 1 and <10% after dose 2.
  • Serious adverse events were reported only in severely immunosuppressed children.
  • Antibody response was seen in 60%-79% of HIV-positive vaccinees after dose 2.
  • Cell-mediated immunity was detected in 67%-83% after dose 2.

Why it matters

Understanding the safety and immunogenicity of varicella vaccination in HIV-positive children is crucial for preventing varicella-zoster virus infections, which can lead to increased morbidity in this population. This information aids clinicians in making informed vaccination decisions.

Source

PubMed · PMID 42108526

Published in Pediatr Infect Dis J. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.